000 03332nam a2200397 c 4500
999 _c7282
_d7282
001 7282
003 ES-MaUEC
005 20201203160830.0
006 a||||fo|||| 00| 0
007 cr nn 008mamaa
008 190530s2019 si a o |||| 0|eng d
020 _a9789811372957
024 7 _a10.1007/978-981-13-7295-7
_2doi
040 _bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aQH438.4
_b.B55 2019 EB
245 0 0 _aBiomarkers in Cancer Therapy :
_bLiquid Biopsy Comes of Age
_cedited by Hideaki Shimada
264 1 _aSingapore
_bSpringer Singapore :
_bImprint: Springer
_c2019.
300 _a1 recurso en línea (VIII, 157 páginas 22 ilustraciones, 17 ilustraciones a color)
336 _2rdacontent
_aTexto (visual)
_btxt
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
347 _atext file
_bPDF
_2rda
490 0 _aMedicine (Springer-11650)
505 0 _aI. General Statement -- 1.Exosomes -- 2.Cell Free DNA -- 3.Autoantibody -- 4.Serum Protein -- Part II. Application to Each Cancer -- 5.Head and Neck Cancer / Esophageal Cancer -- 6.Gastric Cancer -- 7.Colorectal Cancer -- 8.Liver Cancer -- 9.Pancreas Cancer -- 10.Lung Cancer -- 11.Breast Cancer -- 12.Prostate Cancer -- 13.Gynecological Cancers -- 14.Malignant Pleural Mesothelioma.
520 3 _aThis book sheds new light on research into liquid biopsy biomarkers for cancer screening. The chapters in the first half address exosomes, circulating cell-free DNA and autoantibodies, and main solid cancers, along with companion biomarkers – all of which serve as the basis for exploring key research questions for future clinical trials in the book’s second half. The study of biomarkers has evolved rapidly thanks to advances in precision medicine. While conventional cancer biomarker research is focused on proteomics or gene analysis of resected tissue, diagnostic markers have since become significant in terms of gauging the effectiveness of molecularly targeted drugs or the likelihood of a favorable prognosis. In addition, conventional treatment strategy, which draws on archives of resected tissue samples, is now gradually being replaced by monitoring with the use of liquid biopsy, which is poised to become the new mainstream in molecular targeting therapy. The contributing authors discuss in detail biomarkers, molecular targets for treatment, monitoring markers to evaluate treatment responses, prognostic markers, and screening and early diagnosis. Accordingly, this excellent collection of texts will benefit not only oncologists, but also medical and biological researchers and pharmaceutical scientists involved in the latest cancer research.
650 7 _aMarcadores biológicos
_2embne
_9162047
650 7 _aCáncer
_2embne
_9174085
_xTratamiento
700 1 _aShimada, Hideaki.
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
_9106937
776 0 8 _iPrinted edition:
_z9789811372940
776 0 8 _iPrinted edition:
_z9789811372964
776 0 8 _iPrinted edition:
_z9789811372971
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-981-13-7295-7
_zAcceso a este recurso digital (usuarios Universidad Europea de Valencia)
942 _2lcc
_cLE
998 _db
_zSI